HKSE · 9926.HK
Akeso, Inc.
HK$83.45-HK$0.05 (-0.06%)
Akeso, Inc.’s quoted price sits in the lower half of its reported 52-week range, 46.51% below the high.
Loading market information…
HKSE · 6996.HK · HKD
Stock price, earnings
Quote as of Oct 30, 2026, 03:27 AM UTC. Cached market data; not a live quote.
One-year closing-price history · HKD. Historical prices are not a forecast.
Antengene Corporation Limited’s quoted price sits in the lower half of its reported 52-week range, 54.78% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Antengene Corporation Limited’s next earnings report is currently expected on Mar 19, 2027, with estimated earnings per share of HK$0.22. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Antengene Corporation Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Antengene Corporation Limited, a biopharmaceutical firm, is dedicated to developing advanced oncology treatments primarily within the Chinese market. Its active clinical development pipeline includes several innovative compounds. Among these, ATG-016, a next-generation XPO1 inhibitor, is currently undergoing Phase I/II clinical trials for individuals with solid tumors. ATG-527 (Verdinexor) has successfully completed its Phase I evaluation for chronic human viral infections. The company is also advancing ATG-019, a dual PAK4/NAMPT inhibitor targeting non-Hodgkin's lymphoma and advanced solid tumors, and ATG-017, an ERK1/2 inhibitor designed for treating advanced solid tumors and hematologic malignancies. Additionally, ATG-010 (selinexor) is a SINE compound that modulates XPO1. ATG-101, a bispecific PD-L1/4-1BB antibody, is in Phase I studies for patients with metastatic/advanced solid tumors and B-cell non-Hodgkin's lymphoma. Completing its clinical-stage assets is ATG-008 (onatasertib), an orally delivered mTOR kinase inhibitor aimed at solid tumors exhibiting specific genetic alterations like NFE2L2, STK11, and RICTOR. In its earlier, pre-clinical research phase, Antengene is exploring ATG-037, a CD73 inhibitor for advanced or metastatic solid tumors; ATG-018, an ATR inhibitor; ATG-022, a Claudin 18.2 antibody-drug conjugate; ATG-031, a CD24 antibody; ATG-027, a B7H3/PD-L1 bispecific antibody; ATG-032, a LILRB antibody; and ATG-041, an Axl-Mer inhibitor. Founded in 2016, the company maintains its headquarters in Shanghai, China.
Latest available per-share figures in HKD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:43 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q4 2023 | Mar 22, 2024 | -HK$0.65-119.27% vs estimate | -HK$5.21M-102.71% vs estimate |
|---|
| Q2 2023 | Aug 25, 2023 | -HK$0.38+42.59% vs estimate | HK$77.88M-45.36% vs estimate |
|---|
| Q4 2022 | Mar 28, 2023 | -HK$0.84+6.78% vs estimate | HK$120.93M-15.99% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
HK$83.45-HK$0.05 (-0.06%)
Akeso, Inc.’s quoted price sits in the lower half of its reported 52-week range, 46.51% below the high.
HK$11.46-HK$0.21 (-1.8%)
InnoCare Pharma Limited’s quoted price sits in the lower half of its reported 52-week range, 29.26% below the high.
HK$23.36-HK$1.60 (-6.41%)
GenFleet Therapeutics (Shanghai) Inc.’s quoted price sits in the lower half of its reported 52-week range, 55.84% below the high.
HK$4.95+HK$0.21 (+4.44%)
CStone Pharmaceuticals’s quoted price sits in the lower half of its reported 52-week range, 52.5% below the high.
HK$6.34-HK$0.15 (-2.31%)
Alphamab Oncology’s quoted price sits in the lower half of its reported 52-week range, 48.03% below the high.
HK$3.24+HK$0.17 (+5.55%)
Lepu Biopharma Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 52.98% below the high.
HK$8.83+HK$0.18 (+2.02%)
TransThera Sciences (Nanjing). Inc.’s quoted price sits in the lower half of its reported 52-week range, 96.41% below the high.
HK$26.10-HK$0.34 (-1.29%)
Hanx Biopharmaceuticals (Wuhan) Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 22.78% below the high.
